Merdad Parsey
Chief Tech/Sci/R&D Officer chez GILEAD SCIENCES, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Le Dr Merdad V. Parsey est un directeur indépendant chez Arcus Biosciences, Inc. et un directeur médical chez Gilead Sciences, Inc. Il siège au conseil d'administration d'Arcus Biosciences, Inc. et de Sagimet Biosciences, Inc. Auparavant, le Dr Parsey a été employé en tant que directeur médical senior par Regeneron Pharmaceuticals, Inc. et par Genentech, Inc. en tant que directeur médical associé par Merck & Co., Inc. en tant que directeur de la médecine des soins intensifs par la New York University School of Medicine, en tant que membre du groupe Roche et en tant que directeur médical senior par Sunovion Pharmaceuticals, Inc. Il a obtenu son doctorat à l'université du Maryland.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
GILEAD SCIENCES, INC.
0,01% | 01/04/2024 | 96 304 ( 0,01% ) | 7 M $ | 31/03/2024 |
18/07/2023 | 12 794 ( 0,06% ) | 69 343 $ | 31/03/2024 |
Postes actifs de Merdad Parsey
Sociétés | Poste | Début |
---|---|---|
SAGIMET BIOSCIENCES INC. | Director/Board Member | 30/09/2010 |
GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/11/2019 |
ARCUS BIOSCIENCES, INC. | Director/Board Member | 13/07/2020 |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Director/Board Member | - |
Anciens postes connus de Merdad Parsey
Sociétés | Poste | Fin |
---|---|---|
REGENERON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2004 |
New York University School of Medicine | Corporate Officer/Principal | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Chief Tech/Sci/R&D Officer | - |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Formation de Merdad Parsey
University of Maryland | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
REGENERON PHARMACEUTICALS, INC. | Health Technology |
SAGIMET BIOSCIENCES INC. | Health Technology |
ARCUS BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |